Summary Paraffin sections from 30 human breast tissue specimens were stained with a specific antibody for thymosin beta-10, ATBIO(38-43). The results showed that thymosin beta-10 was detected mainly in the malignant tissue, particularly in the cancerous cells, whereas the normal cell population around the lesions showed very weak staining. Also, the intensity of staining in the cancerous cells was proportionally increased with the increasing grade of the lesions.
Thymosin beta-lO belongs to a family of highly conserved peptides and consists of 43 amino acids with a molecular weight of approximately 4.8 kDa (Hannappel et al., 1982) . In most mammalian species studied so far, two betathymosins have been found, and in humans and rats thymosin beta-10 is accompanied by thymosin beta-4, a related protein with 85% structural homology (EricksonViitanen et al., 1983a,b) . Even though thymosin beta-4 and thymosin beta-10 were first isolated in the immune system (Horecker and Morgan, 1984) , their mRNAs have been detected in most tissues (Lin and Morrison-Bogorad, 1990 ), where thymosin beta-4 occurs in significantly larger quantities than thymosin beta-10 (Hall et al., 1991) . According to recent reports, both these thymosins are Gactin-binding proteins in most cell types (Cassimeris et al., 1992; Yu et al., 1993) , and in this manner are believed to play important roles in the functions of the cytoskeleton, of which actin is a crucial component (Yu et al., 1994) . In spite of their structural and functional similarities, different expression patterns have been observed for thymosin beta-4 and thymosin beta-10. For example, while both thymosins are strongly expressed in fetal brain and other fetal organs, thymosin beta-10 levels fall considerably in most adult tissues (Lin and Morrison-Bogorad, 1990; Hall et al., 1990 Hall et al., , 1991 . Lately, their possible association with cancer has aroused interest in this class of peptides. The expression of thymosin beta-10 mRNA was found to be increased in renal cell carcinoma and other types of tumour in comparison with normal tissue (Hall, 1991a) , while other workers have reported that expression of thymosin beta-10 mRNA was associated with metastatic behaviour of human melanoma cell lines in nude mice (Weterman et al., 1993) . Even though the exact molecular mechanism by which thymosin beta-10 may function is unclear, a number of reports present to date support its significant participation in cellular functions with some evidence for its participation in carcinogenesis (see Hall, 1994 for review) .
Expression levels of the thymosin beta-10 protein have not been studied sufficiently, except for one report by Hall et al. (199la) that indicated increased concentrations in tissue extracts using high-performance liquid chromatography (HPLC). In order to investigate and clarify the role of thymosins as potential tumour markers, our laboratory has undertaken research to develop reliable detection assays that are sensitive, reproducible, fast and simple enough for routine use. For this purpose, we produced a specific antibody against the selected carboxy-terminal hexapeptide fragment of thymosin beta-10, the region least homologous with thymosin beta-4, the other beta-thymosin in humans (Goodall and Horecker, 1987) , and adopted an immunohistochemical technique capable of detecting thymosin beta-10 in human specimens in its natural surroundings.
In this paper, we announce very interesting preliminary findings of this immunohistological study on paraffin sections of human breast cancer.
Materials and methods

Primary antibody
The primary antibody, ATB1O(38-43), was produced against the carboxy-terminal peptide fragment (amino acids 38-43), which was prepared using a solid-phase synthesis method (Leondiadis et al., 1996a) . In brief, a New Zealand white rabbit was immunised with the peptide -keyhole limpet haemocyanin (KLH) conjugate emulsified with complete Freund's adjuvant. The first booster dose was given 6 weeks after immunisation, followed by subsequent doses every 4 weeks. The antiserum which was collected 10-12 days after each booster injection was checked for specificity and titre, aliquoted and stored at -35°C until use. The antiserum used in this study was obtained after the third booster dose.
Clinical material
Twenty-five breast tissue samples were collected from female patients aged between 24 and 76 years after they had been examined in the Histopathology Department of the Anticancer Institute at the St Savas Hospital, Athens. Each specimen was fixed in 20% formalin, embedded in paraffin and stored until use.
Histopathologically, breast cancer lesions may be broadly divided into two classes: (1) ductal carcinoma, which comprises 90% of the detected cases; and (2) (Figure 1 ) and in situ carcinoma (Figure 2 ). The two specimens with grade III lesions of myeloid carcinoma also showed strong positivity for thymosin beta-10 (+ + +, Figure 3) , whereas the one specimen with tubular carcinoma in grade I was comparatively less positive (+, Figure 4) . On the other hand, the hyperplastic and premalignant lesions showed weak staining (+), while the benign neoplastic lesions were barely positive for thymosin beta-10 ( Figure 5 ). In control experiments in which nonimmune rabbit serum was used as the primary antibody, no positive reaction was noticed on the sections. The staining pattern of the specimens is summarised in Table II 
Discussion
The results of this blind study show two important aspects of thymosin beta-10 that could come into use for diagnosis and prognosis of breast cancer patients.
Firstly, in all cases that were tested, thymosin beta-10 was highly expressed in the neoplastic cells of human breast cancer when compared with the normal cell population present in the uninvolved tissue. The weak staining of normal tissue was not surprising, because minute amounts of thymosin beta-10 are present in normal human tissue (Hall, 1991a) . However, the distinct staining of cancerous lesions against a relatively weak background using immunohistological methods could be an advantage during histopathological diagnosis of breast cancer. This was particularly evident in in situ ductal carcinoma in which only one particular mammary duct was affected, showing increased thymosin beta-10 expression in comparison with the rest of the tissue (Figure 2) .
Secondly, increased expression of thymosin beta-10 was found to be associated with rising grade and, therefore, reduced differentiation of the cells in the cancerous tissue. addition of a morphogen, such as all-trans retinoic acid, modulates thymosin beta-10 expression depending on the type of cell line used (Hall et al., 1990; Hall, 1991b) , indicates some association cell differentiation might have on thymosin beta-10 expression or vice versa. Similarly, increased thymosin beta-10 mRNA was found in immature rat ovaries treated with human chorionic gonadotropin (Hall et al., 1991) . More work will, however, be needed to clarify further the effect of the state of differentiation on thymosin beta-10 expression in cells and tissues.
The number of patients included in this study limits firm conclusions at present and it is being extended to a larger number of specimens that are expected to provide statistically significant answers. Even so, this preliminary study provides sufficient indication that its high expression in malignant breast tissue and its association with cancer grade could make thymosin beta-10 of potential diagnostic value. It seems that its detection with a specific antibody, such as ATB1O (38 -43) with a routinely used technique, such as immunohistochemistry on paraffin-fixed sections, could contribute immensely during diagnosis and even prognosis of human breast cancer.
